Awiqli 700 Units FlexTouch

Awiqli 700 Units FlexTouch – Once-Weekly Insulin Icodec Injection

Awiqli 700 Units FlexTouch contains Insulin Icodec 700 units in 1 mL. It is a long-acting basal insulin supplied in a disposable, prefilled FlexTouch pen for once-weekly subcutaneous administration in adults with diabetes mellitus, per local prescribing approval. Insulin icodec provides prolonged background insulin activity throughout the week. It helps regulate blood glucose by supporting glucose uptake into body tissues and reducing excess glucose production by the liver. Awiqli must be used only according to the dose prescribed by a diabetes specialist. The required weekly dose depends on current insulin treatment, blood glucose readings, metabolic requirements, other diabetes medicines, and individual treatment response.

Key Features

• Contains Insulin Icodec: A long-acting basal insulin analogue.
• Once-Weekly Administration: Injected on the same day each week.
• 700 Units/ml Concentration: The 1 ml FlexTouch pen contains a total of 700 units.
• Adjustable FlexTouch Pen: Delivers prescribed doses from 10 to 700 units in 10-unit increments.
• Pre-Filled Pen: Designed for convenient subcutaneous administration.
• Prescription Treatment: Requires blood glucose monitoring and medical supervision.

Active Ingredient

• Insulin Icodec 700 units/ml: An ultra-long-acting basal insulin designed for once-weekly blood glucose management.

Uses

• Management of diabetes mellitus in adults where insulin icodec is locally approved.
• Improvement of blood glucose control in adults with type 2 diabetes.
• May be used alone or with other diabetes medicines according to the prescribed treatment plan.
• For adults with type 1 diabetes, it must be combined with mealtime insulin where this indication is approved.

How to Use

• Use Awiqli exactly as prescribed and demonstrated by your healthcare professional.
• Inject it once weekly on the same day each week.
• Administer only as a subcutaneous injection into the abdomen, thigh, or upper arm.
• Rotate injection sites to reduce the risk of skin thickening, pits, lumps, or local reactions.
• Attach a new compatible needle before every injection.
• Check the product name, concentration, and selected dose before injecting.
• Do not inject into a vein or muscle, and do not use in an insulin pump.
• Do not withdraw insulin from the FlexTouch pen using a syringe.
• Never select the maximum 700-unit dose unless it is specifically prescribed.
• Do not alter the weekly dose or switch from another insulin without medical supervision.

Precautions

• Monitor blood glucose as instructed, particularly when starting treatment, changing doses, or switching from another insulin.
• Inform your doctor if you have kidney disease, liver disease, heart failure, low potassium levels, or recurrent hypoglycaemia.
• Tell your healthcare provider about all insulin products, diabetes medicines, prescription medicines, and supplements you use.
• Changes in meals, physical activity, illness, or other medicines may affect blood glucose levels.
• Do not use during an episode of low blood glucose.
• Do not share the FlexTouch pen or needles with another person, even when a new needle is attached.
• Patients with impaired vision should use the pen only with assistance from someone trained in its operation.
• Consult your doctor regarding use during pregnancy or breastfeeding.

Warning

• Hypoglycaemia: Low blood glucose is the most common adverse effect of insulin and may become severe or life-threatening.
• The prolonged action of Awiqli may delay recovery from hypoglycaemia compared with shorter-acting insulin.
• Medication Errors: Incorrect dose selection or confusion with another injectable medicine may cause serious hypoglycaemia or hyperglycaemia.
• Allergic Reactions: Seek emergency assistance for facial swelling, difficulty breathing, a widespread rash, dizziness, or a rapid heartbeat.
• Low Potassium: Insulin may lower blood potassium levels, particularly in susceptible patients.
• Seek urgent help for severe weakness, confusion, seizures, unconsciousness, or symptoms of dangerously low blood glucose.
• Changes to the insulin regimen must be made under close medical supervision.

Common Side Effects

• Low blood glucose.
• Injection-site redness, itching, swelling, or discomfort.
• Weight gain.
• Swelling of the hands or feet.
• Skin thickening, pits, or lumps at repeatedly used injection sites.
• Rash or itching.

Storage

• Before first use, store in a refrigerator between 2°C and 8°C.
• Do not freeze or store directly next to the refrigerator cooling element.
• Do not use the pen if it has been frozen.
• After first use, the pen may be stored for up to 12 weeks below 30°C or in a refrigerator between 2°C and 8°C.
• Keep the pen cap attached to protect the medicine from light.
• Remove and safely discard the needle after every injection.
• Keep the pen away from excessive heat and direct sunlight.
• Keep out of reach of children.

Legal Disclaimer: Awiqli 700 Units FlexTouch is a concentrated prescription insulin intended for once-weekly use under qualified medical supervision. Approved indications may differ between countries. Incorrect dose selection can cause severe or prolonged hypoglycaemia. This information is provided for educational purposes only and should not replace medical advice, diabetes training, blood glucose monitoring, or the official instructions supplied with the medicine.